What are the biggest challenges in bringing a product to market? From concept to funding and every stage in-between it takes a strong leadership team to achieve success, especially in today’s highly competitive environment. Hear at first-hand how OxSonics a University of Oxford spin-out company developing a new generation of ultrasound-based medical devices, successfully secured a major £2.1million Biomedical Catalyst award from the UK’s innovation agency, the Technology Strategy Board. Coupled with OxSonics initial financing of £2.7m in January 2014, the company has now raised a total of £4.8m.
Dr Colin Story, Founder & CEO of OxSonics will be Oxford Start Up Grind guest on Wednesday 26th November, starting at 6pm at Launchpad Said Business School. Start Up Grind events provide audience with a first-hand opportunity to hear the real stories behind the success and we are delighted to be supporting this exciting evening.
This event is free of charge, but we do need you to register, as we have a limited number of tickets available. To book your place please click here. Tickets will be strictly allocated on a first come first served basis. Guests will be invited to submit questions in advance.
Dr Colin Story brings over 17 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd., where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd. as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became an Executive Director and the Chief Executive Officer of OxSonics Ltd.